Organization & Developments: Nabriva Therapeutics

Parents

2019: FDA OKs Nabriva antibiotic_seekingalpha.com
2019: Manufacturing concerns spike Nabriva’s plans to launch its first antibiotic
2019: Nabriva Therapeutics: 2 Novel Antibiotics, 2 Sets Of Problems_seekingalpha.com
2019: The Lowdown On Nabriva_seekingalpha.com
2023: An antibiotics biotech begins wind-down, lays off nearly all workers_
2023: Antibiotic developer Nabriva to wind down _cen.acs.org
Nabriva was originally founded in Austria as a spin-off from Sandoz GmbH in 2005 and went public in 2015
The company has two primary assets. One (Xenleta) received FDA approval on August 19, 2019, for the other (Contepo), Nabriva received a CRL in April 2019.